TB prevention strategies and unanswered questions for pregnant and postpartum women living with HIV: the need for improved evidence

Citation: Mathad JS, LaCourse SM, Gupta A. TB prevention strategies and unanswered questions for pregnant and postpartum women living with HIV: the need for improved evidence. J Int AIDS Soc. 2020 Mar;23(3):e25481. doi: 10.1002/jia2.25481. PMID: 32202066.

Access full article:

https://www.ncbi.nlm.nih.gov/pubmed/32202066

To end the tuberculosis (TB) epidemic, the World Health Organization (WHO) recommends improving access to testing and treatment of latent TB infection (LTBI) [1]. Despite recent epidemiologic studies demonstrating an approximately twofold increased risk of active TB in peripartum women [2], and poor outcomes associated with TB during pregnancy for mothers and their infants [3, 4], lack of data has prevented comprehensive inclusion of pregnant and postpartum women in guidelines and remains a critical gap in our efforts to address TB globally.

Categories

CRS
Topics

Clinical Trials

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate...

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

Read More

A5320: Viral Hepatitis C Infection Long-term Cohort Study...

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...

Read More

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More